Phathom Pharmaceuticals (PHAT) Interest & Investment Income (2019 - 2026)

Phathom Pharmaceuticals (PHAT) has 8 years of Interest & Investment Income data on file, last reported at $1.7 million in Q1 2026.

• Interest & Investment Income for Q1 2026 came in at $1.7 million, down 34.24% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.1 million (down 54.47% YoY), and the FY2025 annual result was $7.0 million, down 53.53% from the prior year.
• Interest & Investment Income climbed to $1.7 million in Q1 2026 per PHAT's latest filing, from $1.2 million in the prior quarter.
• Over five years, Interest & Investment Income peaked at $4.3 million in Q1 2024 and troughed at $7000.0 in Q1 2022.
• A 5-year average of $2.0 million and a median of $1.7 million in 2026 frame the typical range for Interest & Investment Income.
• The sharpest annual moves came in 2022 and 2025: Interest & Investment Income soared 21350.0% in 2022, then sank 65.7% in 2025.
• A 5-year view of Interest & Investment Income shows it stood at $1.3 million in 2022, then jumped by 160.14% to $3.3 million in 2023, then advanced by 4.84% to $3.5 million in 2024, then slumped by 65.7% to $1.2 million in 2025, then surged by 44.19% to $1.7 million in 2026.
• Business Quant data shows PHAT's Interest & Investment Income at $1.7 million in Q1 2026, $1.2 million in Q4 2025, and $1.4 million in Q3 2025.